Technology
Health
Biotechnology

XBiotech

$11.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (3.77%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell XBiotech and other stocks, options, ETFs, and crypto commission-free!

About

XBiotech Inc. Common Stock, also called XBiotech, is a biopharmaceutical company, which engages in development and commercialization of therapeutic antibodies based on its True Human™ proprietary technology. Read More Its product pipeline include oncology, infectious diseases, dermatology, and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Employees
51
Headquarters
Austin, Texas
Founded
2005
Market Cap
380.54M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
98.26K
High Today
$11.17
Low Today
$10.46
Open Price
$10.60
Volume
136.17K
52 Week High
$11.17
52 Week Low
$2.13

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2015 IPO
US

News

Simply Wall StMar 8

Who Has Been Buying XBiotech Inc. (NASDAQ:XBIT) Shares?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we’ll take a look at whether insiders have been buying or selling shares in XBiotech Inc. (NASDAQ:XBIT). What Is Insider Buying? It’s quite normal to see company insiders, such as board members, trading in company stock, from time to time. However, such insiders must disclose their trad...

397
Associated PressMar 5

Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Significant therapeutic benefit achieved whether or not patients had previously failed treatment with existing FDA-approved biological drug.- 61-63% of patients achieved a positive HiSCR (the accepted measure of disease seve...

214
Associated PressMar 1

Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

-- Rapid and significant reduction in skin lesions, 66% (p<0.001) and 76% (p<0.001) mean reduction in EASI score in 4 and 7 weeks, respectively.

20

Earnings

-$0.26
-$0.17
-$0.09
$0.00
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.17 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.